{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:57:10Z","timestamp":1761058630115},"reference-count":81,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2007,2,26]],"date-time":"2007-02-26T00:00:00Z","timestamp":1172448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2007,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Peripheral arterial disease (PAD) is strongly associated with atherosclerosis in the coronary and carotid arteries, leading to a highly increased incidence of myocardial infarction, ischaemic stroke and cardiovascular death. Fortunately, pharmacological interventions in large clinical trials have been as effective in subgroups of patients with PAD as in subjects with other atherosclerotic disease. Antiplatelet treatment is indicated in virtually all patients with PAD. Aspirin 75\u2013325\u00a0mg\u00a0day<jats:sup>\u22121<\/jats:sup> is considered as first\u2010line treatment, and clopidogrel 75\u00a0mg\u00a0day<jats:sup>\u22121<\/jats:sup> is an effective alternative. Statin therapy is indicated to achieve a target low\u2010density lipoprotein cholesterol level of \u2264\u00a02\u00b75\u00a0mmol\u00a0L<jats:sup>\u22121<\/jats:sup> in patients with PAD and there is emerging evidence that even lower levels are beneficial. Lowering of plasma homocysteine by supplementing folic acid, vitamin B<jats:sub>12<\/jats:sub> and vitamin B<jats:sub>6<\/jats:sub> is not recommended in patients with mild to moderate hyperhomocysteinaemia in the 12\u201325\u00a0\u00b5mol\u00a0L<jats:sup>\u22121<\/jats:sup> range, since it does not reduce the incidence of cardiovascular events. Antihypertensive treatment is indicated to achieve a goal blood pressure of \u2264\u00a0140\/90\u00a0mmHg or\u00a0\u2264\u00a0130\/80\u00a0mmHg in the presence of diabetes or chronic kidney disease. All classes of antihypertensive drugs are acceptable for treatment of hypertension in patients with PAD, but angiotensin\u2010converting enzyme inhibitors ramipril or perindopril are especially appropriate because they reduce the incidence of cardiovascular events beyond their blood pressure\u2010lowering effects. Beta\u2010blockers should not be used as first\u2010line antihypertensive treatment. Diabetic patients with PAD should reduce their glycosylated haemoglobin to \u2264\u00a07%. In conclusion, pharmacological secondary prevention of cardiovascular morbidity and mortality in patients with PAD should be as comprehensive as that in patients with established coronary or cerebrovascular disease.<\/jats:p>","DOI":"10.1111\/j.1365-2362.2007.01767.x","type":"journal-article","created":{"date-parts":[[2007,2,27]],"date-time":"2007-02-27T00:08:58Z","timestamp":1172534938000},"page":"157-164","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease"],"prefix":"10.1111","volume":"37","author":[{"given":"A.","family":"Blinc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Poredo\u0161","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,2,26]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"97","article-title":"A clinical approach to the management of the patient with coronary (Co) and\/or carotid (Ca) artery disease who presents with leg ischemia (Lis)","volume":"19","author":"Clement DL","year":"2000","journal-title":"Int Angiol"},{"issue":"1","key":"e_1_2_5_3_2","first-page":"1","article-title":"Management of peripheral arterial disease \u2013 Transatlantic inter\u2010society consensus. Introduction","volume":"19","author":"The TASC Working Group.","year":"2000","journal-title":"Int Angiol"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(01)00551-X"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1191\/1358863x04vm514ra"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1262-3636(07)70215-X"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.25194"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202063260605"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.82.6.1925"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(91)90014-T"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.88.3.837"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1997.tb03198.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.19.3.538"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200001203420301"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7329.71"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6922.159"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614560"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)93216-A"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi684"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01351.x"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060989"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010746"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050522"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67660-X"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05701-4"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.19.2411"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051303"},{"issue":"1","key":"e_1_2_5_30_2","first-page":"57","article-title":"Management of peripheral arterial disease \u2013 Transatlantic inter\u2010society consensus. Intermittent claudication","volume":"19","author":"The TASC Working Group.","year":"2000","journal-title":"Int Angiol"},{"key":"e_1_2_5_31_2","unstructured":"ACC\/AHA Practice Guidelines: Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease.ACC\/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity Renal Mesenteric and Abdominal Aortic). Available at:http:\/\/www.acc.org\/clinical\/guidelines\/pad\/index.pdf."},{"key":"e_1_2_5_32_2","first-page":"233","article-title":"Prevalence of peripheral arterial occlusive disease and associated risk factors in a sample of southern Sardinian population","volume":"13","author":"Binaghi F","year":"1994","journal-title":"Int Angiol"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)02616-4"},{"key":"e_1_2_5_34_2","first-page":"CD000123","article-title":"Lipid\u2010lowering for lower limb atherosclerosis","volume":"2","author":"Leng GC","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7373.1139"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00904-1"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199010043231404"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6060(96)80016-X"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.83.2.438"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-12-199612150-00001"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000050380.64025.07"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000090686.57897.F5"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03530130055028"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-5-199909070-00008"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7374.1202"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.16.2023"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.16.2015"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055227"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060900"},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.10.064"},{"key":"e_1_2_5_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001209"},{"key":"e_1_2_5_52_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.11.1317"},{"key":"e_1_2_5_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1985.tb02853.x"},{"key":"e_1_2_5_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90128-7"},{"key":"e_1_2_5_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(95)05657-2"},{"key":"e_1_2_5_56_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000049640.46039.52"},{"key":"e_1_2_5_57_2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1001\/archinte.1991.00400070161023","article-title":"The treatment of mild hypertension study. A randomized, placebo\u2010controlled trial of a nutritional\u2010hygienic regimen along with various drug monotherapies","volume":"151","author":"The Treatment of Mild Hypertension Research Group.","year":"1991","journal-title":"Arch Intern Med"},{"key":"e_1_2_5_58_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.1967"},{"key":"e_1_2_5_59_2","doi-asserted-by":"publisher","DOI":"10.1191\/1358863x05vm591xx"},{"key":"e_1_2_5_60_2","unstructured":"The National Collaborating Centre for Chronic Conditions.Management of hypertension in adults in primary care: partial update. Available at:http:\/\/www.nice.org.uk\/page.aspx?o=CG034fullguideline."},{"key":"e_1_2_5_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67185-1"},{"key":"e_1_2_5_62_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1991.00400090063012"},{"key":"e_1_2_5_63_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200306000-00001"},{"issue":"3","key":"e_1_2_5_64_2","first-page":"S25","article-title":"New evidence from the CAPRICORN Trial: the role of carvedilol in high\u2010risk, post\u2010myocardial infarction patients","volume":"4","author":"Sackner\u2010Bernstein JD","year":"2003","journal-title":"Rev Cardiovasc Med"},{"key":"e_1_2_5_65_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:HREV.0000046367.99002.a4"},{"key":"e_1_2_5_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.05.039"},{"key":"e_1_2_5_67_2","doi-asserted-by":"publisher","DOI":"10.1177\/107424840400900207"},{"key":"e_1_2_5_68_2","doi-asserted-by":"publisher","DOI":"10.5414\/CPP44344"},{"key":"e_1_2_5_69_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262090-00016"},{"key":"e_1_2_5_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2003.10.033"},{"key":"e_1_2_5_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14286-9"},{"key":"e_1_2_5_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08089-3"},{"key":"e_1_2_5_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14282-1"},{"key":"e_1_2_5_74_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291401"},{"key":"e_1_2_5_75_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200002103420603"},{"key":"e_1_2_5_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)80683-3"},{"key":"e_1_2_5_77_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052187"},{"key":"e_1_2_5_78_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-051X.1988.tb01003.x"},{"key":"e_1_2_5_79_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.29.04.06.dc05-2018"},{"key":"e_1_2_5_80_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2007.01747.x"},{"issue":"1","key":"e_1_2_5_81_2","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2337\/diacare.29.s1.06.s4","article-title":"Standards of medical care in diabetes","volume":"29","author":"American Diabetes Association.","year":"2006","journal-title":"Diabetes Care"},{"key":"e_1_2_5_82_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2000.00336.x"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2362.2007.01767.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2362.2007.01767.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T06:54:45Z","timestamp":1697180085000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2362.2007.01767.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,26]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["10.1111\/j.1365-2362.2007.01767.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2362.2007.01767.x","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,26]]}}}